M&A Deal Summary

Nicox Acquires Aciex Therapeutics

On October 24, 2014, Nicox acquired life science company Aciex Therapeutics from Bay City Capital and Akorn for 120M USD

Acquisition Highlights
  • This is Nicox’s 1st transaction in the Life Science sector.
  • This is Nicox’s largest (disclosed) transaction.
  • This is Nicox’s 1st transaction in the United States.
  • This is Nicox’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2014-10-24
Target Aciex Therapeutics
Sector Life Science
Buyer(s) Nicox
Sellers(s) Bay City Capital
Akorn
Deal Type Add-on Acquisition
Deal Value 120M USD
Advisor(s) Aquilo Partners LP (Financial)
Wilmer Cutler Pickering Hale and Dorr LLP (Legal)

Target

Aciex Therapeutics

Boston, Massachusetts, United States
website
Aciex Therapeutics, Inc. is an ophthalmic pharmaceutical company centered on developing first in class products to treat ocular diseases.

Search 193,605 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Nicox

Valbonne, France

website

Category Company
Founded 1996
Sector Life Science
Employees34
Revenue 5M EUR (2022)
DESCRIPTION

Nicox is an international company focused on the ophthalmic market. With a heritage of innovative R&D, business development and commercial expertise, the Nicox team is building a diversified portfolio of therapies and diagnostic tools that can help people to enhance their sight. Nicox was founded in 1996 and is based in Valbonne, France.

DEAL STATS #
Overall 4 of 4
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 4 of 4
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2014) 3 of 3
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-09-16 AVEye Biotechnologie

Vienna, Austria

AVEye Biotechnologie GmbH develops Carragelose, an anti-viral eye drop program.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-11-17 NicOx

Warren Township, New Jersey, United States

NicOx, Inc. distributes nitric oxide (NO)-donating drug.

Sell $20M

Seller(S) 2

SELLER

Bay City Capital

San Rafael, California, United States

Investor Investor Investor Investor Investor

website

Category Venture Capital Firm
Founded 1997
PE ASSETS 1.3B USD
Size Large
Type Sector Focused
DESCRIPTION

Bay City Capital LLC was established in 1997 as an equal partnership between The Craves Group and certain Pritzker family business interests for the purpose of managing investment funds in the life sciences industry. Bay City looks for opportunities at all stages of development in biopharmaceuticals, drug discovery, medical devices and diagnostics. Bay City Capital is based in San Francisco, California.

DEAL STATS #
Overall 53 of 62
Sector (Life Science) 37 of 45
Type (Add-on Acquisition) 28 of 31
State (Massachusetts) 6 of 8
Country (United States) 51 of 59
Year (2014) 5 of 6
Size (of disclosed) 12 of 18
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-10-03 Dermira

Menlo Park, California, United States

Dermira, Inc. is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira was founded in 2010 and is based in Menlo Park, California.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-11-06 Nevro

Redwood City, California, United States

Nevro is a medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro was founded in 2006 and is based in Redwood City, California.

Sell -
SELLER

Akorn

Lake Forest, Illinois, United States

website

Category Company
Founded 1971
Sector Life Science
Employees1,972
Revenue 1.1B USD (2016)
DESCRIPTION

Akorn, Inc. is a niche generic pharmaceutical company engaged in the development, manufacture and marketing of multi-source and branded pharmaceutical products in the areas of ophthalmology, antidotes, anti-infectives, and controlled substances for pain management and anesthesia in the United States and across the globe. Akorn, Inc. was founded in 1971 and is based in Lake Forest, Illinois.

DEAL STATS #
Overall 2 of 4
Sector (Life Science) 1 of 2
Type (Add-on Acquisition) 1 of 1
State (Massachusetts) 1 of 1
Country (United States) 2 of 4
Year (2014) 2 of 2
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-09-30 Xopenex Inhalation Solution

United States

Xopenex (levalbuterol HCl) Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.

Buy $45M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-05-27 Akorn - Consumer Health Business

Lake Forest, Illinois, United States

Akorn's Consumer Health Business primarily consists of the following over-the-counter brands: TheraTears, Diabetic Tussin, MagOx, Multi-betic, and Zostrix. The business optimizes the core prescription drug portfolio and enhances our capacity to make growth-oriented investments.

Sell $230M
Mergr

Product

Company

Legal